{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-221626","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2026-05-13T20:10:18+00:00","discovered_at":"2026-05-13T20:11:00.402181+00:00","generated_at":"2026-05-13T22:06:26.562137+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acrivon Q1 net loss $19.0M; cash $97.7M; key ACR-368 interim readout in H2 2026","bullets":["Net loss $19.0M vs $19.7M YoY; R&D $15.2M, G&A $4.7M.","Cash & equivalents $97.7M at March 31, 2026; plus $7.3M from equity financing, runway into Q3 2027.","ACR-368 Phase 2b registrational study: prespecified interim analysis of serous EC arms planned in H2 2026.","ACR-2316 Phase 1/2 shows tolerability and durable activity in AP3-prioritized lung cancers; expansion phase ongoing.","CDK11 inhibitor program (ACR-6840) IND submission targeted for H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-221626","json":"https://secwatch.observer/filing/0001193125-26-221626.json","markdown":"https://secwatch.observer/filing/0001193125-26-221626.md","text":"https://secwatch.observer/filing/0001193125-26-221626.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526221626/0001193125-26-221626-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526221626/acrv-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:06:26.562137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}